NYSEAMERICAN:NBYNovaBay Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.86 0.00 (-0.36 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$0.84Now: $0.86▼$0.8650-Day Range$0.45MA: $0.66▼$1.1952-Week Range$0.24Now: $0.86▼$4.04Volume11,717 shsAverage Volume2.84 million shsMarket Capitalization$24.69 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingNovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.10, NovaBay Pharmaceuticals has a potential upside of 28.4% from its current price of $0.86.Amount of Analyst CoverageNovaBay Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesNovaBay Pharmaceuticals has received 244 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovaBay Pharmaceuticals has received 217 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovaBay Pharmaceuticals has received 52.93% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote “Outperform” if you believe NBY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovaBay Pharmaceuticals does not currently pay a dividend.Dividend GrowthNovaBay Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.22 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:NBY Previous Symbol CUSIPN/A CIK1389545 Webnovabay.com Phone+1-510-8998800Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees70 Outstanding Shares28,811,000Market Cap$24.69 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable AMEX:NBY Rates by TradingView Receive NBY News and Ratings via Email Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of NovaBay Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NovaBay Pharmaceuticals. When is NovaBay Pharmaceuticals' next earnings date? NovaBay Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for NovaBay Pharmaceuticals. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The biopharmaceutical company earned $1.89 million during the quarter. View NovaBay Pharmaceuticals' earnings history. When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work? NovaBay Pharmaceuticals shares reverse split before market open on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split. What price target have analysts set for NBY? 1 Wall Street analysts have issued 12-month price targets for NovaBay Pharmaceuticals' stock. Their forecasts range from $1.10 to $1.10. On average, they anticipate NovaBay Pharmaceuticals' share price to reach $1.10 in the next year. This suggests a possible upside of 28.4% from the stock's current price. View analysts' price targets for NovaBay Pharmaceuticals. Has NovaBay Pharmaceuticals been receiving favorable news coverage? Media headlines about NBY stock have trended positive on Tuesday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NovaBay Pharmaceuticals earned a coverage optimism score of 2.6 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutNovaBay Pharmaceuticals. Are investors shorting NovaBay Pharmaceuticals? NovaBay Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 324,300 shares, a decline of 20.5% from the April 30th total of 407,800 shares. Based on an average daily trading volume, of 3,950,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.9% of the shares of the stock are sold short. View NovaBay Pharmaceuticals' Current Options Chain. Who are some of NovaBay Pharmaceuticals' key competitors? Some companies that are related to NovaBay Pharmaceuticals include CorMedix (CRMD), Cohbar (CWBR), 22nd Century Group (XXII), Ampliphi Biosciences (APHB), Altimmune (ALT), Predictive Technology Group (PRED), Ibio (IBIO), Orgenesis (ORGS), Circassia Pharmaceuticals (CIR), AquaBounty Technologies (AQB), Novoheart (NVH), Immunoprecise Antibodies (IPA), Omega Diagnostics Group (ORPH), Ampio Pharmaceuticals (AMPE) and Ampio Pharmaceuticals (AMPE). View all competitors. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Gilead Sciences (GILD), Novavax (NVAX), Inovio Pharmaceuticals (INO), Opko Health (OPK), Biocept (BIOC), Advanced Micro Devices (AMD), CorMedix (CRMD), Exelixis (EXEL), NVIDIA (NVDA) and Arbutus Biopharma (ABUS). Who are NovaBay Pharmaceuticals' key executives? NovaBay Pharmaceuticals' management team includes the following people: Mr. Justin M. Hall, Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 41)Mr. Jason Philip Raleigh, Interim CFO, Treasurer & Corp. Controller (Age 42)Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 74) What is NovaBay Pharmaceuticals' stock symbol? NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY." How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is NovaBay Pharmaceuticals' stock price today? One share of NBY stock can currently be purchased for approximately $0.86. How big of a company is NovaBay Pharmaceuticals? NovaBay Pharmaceuticals has a market capitalization of $24.69 million. NovaBay Pharmaceuticals employs 70 workers across the globe. What is NovaBay Pharmaceuticals' official website? The official website for NovaBay Pharmaceuticals is novabay.com. How can I contact NovaBay Pharmaceuticals? NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800. This page was last updated on 6/2/2020 by MarketBeat.com Staff
